Personalis files prospectus supplement for up to $100 million stock offering

Personalis, Inc. (NASDAQ:PSNL) announced Friday that it has filed a prospectus supplement related to the potential offer and sale of up to $100 million of its common stock. The filing was made as part of the company’s shelf registration statement on Form S-3.

According to the company’s statement, the shares may be offered and sold under an amended and restated at-the-market (ATM) sales agreement dated December 27, 2024. Piper Sandler & Co. and BTIG, LLC are listed as sales agents under this agreement.

The prospectus supplement, filed Friday, is in addition to Personalis’ existing offering of common stock under a previous sales agreement prospectus dated December 27, 2024, which is also included in the registration statement.

The company included an opinion from Cooley LLP regarding the shares offered, which was filed as an exhibit to the current report.

This information is based on a statement in a regulatory filing with the Securities and Exchange Commission. Personalis, Inc. is headquartered in Fremont, California, and its common stock is traded on the Nasdaq Global Market under the symbol PSNL.

In other recent news, Personalis Inc reported its third-quarter 2025 earnings, revealing a revenue of $14.5 million, which surpassed the forecast of $13.31 million. However, the company’s EPS came in at -$0.24, slightly better than the expected -$0.28. Despite this revenue beat, the company lowered its full-year 2025 revenue guidance. In a significant development, Personalis received Medicare coverage for its NeXT Personal test for breast cancer, with coverage effective retroactively as of October 7, 2025. The reimbursement rates are set at $3,878 for the NeXT Personal Dx Breast MRD Recurrence Monitoring Test and $1,158 for the NeXT Personal Single Plasma Test. Additionally, the Centers for Medicare & Medicaid Services updated reimbursement rates for these tests, which will take effect on December 1, 2025. Analysts at BTIG and Needham have responded positively, raising their price targets to $12.00 and $10.00, respectively, while maintaining a Buy rating. These changes reflect optimism about the company’s molecular testing growth and the impact of the Medicare decision.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.